Board of Directors
CASSS is governed by a volunteer Board of Directors. The Board is responsible for setting organizational policy, planning and allocating resources effectively, providing fiscal oversight and accountability, and ensuring legal and ethical integrity throughout the organization.
Our current board members are listed below:
President
Jamie Moore
SVP, Global Head of Technical Development
Gilead Sciences
Vice President and Secretary
CMC Biotech-MAS Consulting
Treasurer
Joseph Kutza
Senior Director, Regulatory CMC Policy
Eli Lilly and Company
Board Members
Novo Nordisk, Inc.
Christof Finkler
Senior Portfolio and Technical Advisor for Biotech Development
F. Hoffmann-La Roche Ltd.
Nomalie Jaya
Senior Director, Product Quality
Pfizer, Inc.
BioMarin Pharmaceutical Inc.
Genentech, a Member of the Roche Group
Sandoz
Sana Biotechnology
Tune Therapeutics
Associate Directors
One of the priorities of the Board has been to broaden member participation at all levels. If you have volunteered on any CASSS organizing committee, you are invited to become an Associate Director and further help direct the future of CASSS. Together, our volunteers advance the CASSS community in the direction of dignity, respect, scientific truth, and the betterment of humanity.
According to CASSS’ bylaws, the Associate Director’s responsibilities include:
- Advise the Board of Directors on policy and strategic direction for the organization.
- Elect the Board of Directors.
- Nominate and select the CASSS Award recipient.
- Have a direct impact on CASSS’ future.
What are the requirements to become an Associate Director?
- A passion for the mission and vision of CASSS.
- Attending at least one CASSS Symposium or Forum every three years.
- Actively participate in the affairs of CASSS by participating in approximately two Associate Director’s meetings annually (in-person when possible, otherwise via teleconference).
- Participate in the election of the Board of Directors.
Hear from Associate Directors about their CASSS experience:
Jenny Chen, Apellis Pharmaceuticals, Inc.
Ken Miller, BioMarin Pharmaceutical Inc.